Moreover, targeting TNF-α, IL-1β, or IL-33 in rheumatic diseases reduce neutrophil recruitment and pain (Verri et al., 2008, 2010; Amaral et al., 2012, 2016). Here, IL33 is linked to rheumatic disorder.